Different Radioactivity Uptake between Somatostatin Analogues Labelled with In-111 and Y-90/88 in Rat Kidney

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11160%2F12%3A10124209" target="_blank" >RIV/00216208:11160/12:10124209 - isvavai.cz</a>

Výsledek na webu

<a href="http://ar.iiarjournals.org/content/32/3/815.full" target="_blank" >http://ar.iiarjournals.org/content/32/3/815.full</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Different Radioactivity Uptake between Somatostatin Analogues Labelled with In-111 and Y-90/88 in Rat Kidney

Popis výsledku v původním jazyce

Somatostatin receptor targeting is a valuable method to treat somatostatin receptor-positive tumours. In peptide receptor radionuclide therapy, it is essential to determine the highest activity that can be safely administered to the patient. As Y-90 emits no gamma rays, absorbed doses for Y-90 are usually estimated using the same peptide labelled with In-111. The aim of the study was to determine if replacement of Y-90/88 by In-111 affects the biodistribution profile of five selected somatostatin analogues in preclinical experiments. Materials and Methods: Radiolabelled peptides were atministered in to male Wistar rats. Results: The peptides under studs, labelled either with In-111 or with Y-88/90 showed similar distribution profiles in all tissues excepting the kidney. The kidney radioactivity uptake was significantly lower for Y-88/90-labeled peptide in comparison with the one of In-111. Conclusion: We conclude that a radiation-absorbed dose after Y-90-labelled somatostatin analogues

Název v anglickém jazyce

Different Radioactivity Uptake between Somatostatin Analogues Labelled with In-111 and Y-90/88 in Rat Kidney

Popis výsledku anglicky

Somatostatin receptor targeting is a valuable method to treat somatostatin receptor-positive tumours. In peptide receptor radionuclide therapy, it is essential to determine the highest activity that can be safely administered to the patient. As Y-90 emits no gamma rays, absorbed doses for Y-90 are usually estimated using the same peptide labelled with In-111. The aim of the study was to determine if replacement of Y-90/88 by In-111 affects the biodistribution profile of five selected somatostatin analogues in preclinical experiments. Materials and Methods: Radiolabelled peptides were atministered in to male Wistar rats. Results: The peptides under studs, labelled either with In-111 or with Y-88/90 showed similar distribution profiles in all tissues excepting the kidney. The kidney radioactivity uptake was significantly lower for Y-88/90-labeled peptide in comparison with the one of In-111. Conclusion: We conclude that a radiation-absorbed dose after Y-90-labelled somatostatin analogues

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2012

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Anticancer Research

ISSN

0250-7005

e-ISSN

—

Svazek periodika

32

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

GR - Řecká republika

Počet stran výsledku

8

Strana od-do

815-822

Kód UT WoS článku

000301619200017

EID výsledku v databázi Scopus

—